SGM
BBIO icon

Skye Global Management’s BridgeBio Pharma BBIO Stock Holding History

Skye Global Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,000
Closed -$671K – 62
2021
Q2 		$671K Buy
+11,000
New +$628K 0.01% 58

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skye Global Management's BBIO Position: Q3 2021 in Review

Skye Global Management sold out of BridgeBio Pharma (BBIO) in Q3 2021, closing a stake of 11,000 shares — an estimated $671K sold.

Skye Global Management first reported a position in BBIO in Q2 2021 and held it in 1 quarter. The position peaked at $671K in Q2 2021. 210 funds tracked by Wall St. Rank hold BBIO as of Q3 2021.

  • Skye Global Management reported no remaining BridgeBio Pharma position as of Q3 2021 after selling out during the quarter.
  • Skye Global Management sold 11,000 BridgeBio Pharma shares in Q3 2021, an estimated $671K.
  • Skye Global Management first reported a position in BridgeBio Pharma in Q2 2021 and held it in 1 quarter.
  • Skye Global Management's BridgeBio Pharma position peaked at $671K in Q2 2021.
  • 210 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2021.

Based on Skye Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.